ABSTRACT
Heparin is used to decrease the risk of thromboembolic complications during electrophysiology studies (EPS); however, there is wide practice variation and minimal evidence to guide heparin dosing, particularly in pediatric patients. This study retrospectively analyzed heparin dosing and response, measured via activated clotting time (ACT), in patients undergoing EPS and used these data (pre-protocol cohort, n = 40), as well as guidance from available literature to implement a standardized heparin protocol (phase 1, n = 43). We utilized quality improvement methodology to refine this protocol (phase 2, n = 40) to improve therapeutic heparin response. Prior to the protocol, patients achieved therapeutic ACT levels (250-350 s) only 35% of the time which improved to 60% during phase 1 (p < 0.05) and to 73% during phase 2 (p < 0.001 compared to pre-protocol). There were no thromboses or significant adverse events in any group. These results demonstrate the effectiveness of a standardized heparin protocol in achieving effective antithrombotic therapy during left-sided pediatric EPS.
Subject(s)
Anticoagulants/administration & dosage , Catheter Ablation/methods , Heparin/administration & dosage , Thromboembolism/prevention & control , Adolescent , Anticoagulants/pharmacokinetics , Child , Cohort Studies , Dose-Response Relationship, Drug , Electrophysiological Phenomena , Female , Heparin/pharmacokinetics , Humans , Male , Retrospective Studies , Whole Blood Coagulation Time , Young AdultABSTRACT
Iron deficiency (FeD), with or without anemia, in adults with heart failure (HF) is associated with poor outcomes, which can be improved with replacement therapy. A similar therapeutic opportunity may exist for children; however, iron laboratory measurements and FeD have not been described in pediatric patients with HF. A single-center, retrospective study was conducted on 28 patients <21 years old with a diagnosis of dilated cardiomyopathy and HF who had iron laboratories (serum iron, iron saturation, and ferritin) performed. The mean (standard deviation) age at time of laboratory collection was 10.3 (5.5) years. Twenty-seven patients (96.4%) met the criteria for FeD. Serum iron and iron saturation were significantly associated with inpatient hospitalization, being on inotropic medications, or having stage D HF. Low-serum iron was associated with a higher left ventricular end-diastolic dimension and left ventricular end-systolic dimension z-score by echocardiography ((ß -2.58, 95% confidence interval [CI] -4.76, -0.40, p = 0.02) and (ß -2.43, 95% CI -4.70, -0.17, p = 0.04)), respectively. Low ferritin was associated with higher mortality (relative risk 0.29, 95% CI 0.12, 0.70, p = 0.006). In conclusion, FeD was common in this pediatric cohort with more advanced HF. Iron profile abnormalities were associated with worse HF severity and outcomes including mortality.
Subject(s)
Anemia, Iron-Deficiency/blood , Cardiomyopathy, Dilated/complications , Heart Failure/blood , Heart Ventricles/physiopathology , Iron Deficiencies , Ventricular Function, Left/physiology , Anemia, Iron-Deficiency/complications , Biomarkers/blood , Cardiomyopathy, Dilated/blood , Cardiomyopathy, Dilated/diagnosis , Child , Disease Progression , Echocardiography , Female , Ferritins/blood , Follow-Up Studies , Heart Failure/diagnosis , Heart Failure/etiology , Heart Ventricles/diagnostic imaging , Humans , Iron/blood , Male , Prognosis , Retrospective Studies , Stroke VolumeABSTRACT
A 6-year-old child developed heparin-induced thrombocytopenia while on extracorporeal life support. Hours after a difficult transition from heparin to argatroban for anticoagulation therapy, the child underwent heart transplantation. Intraoperative management was plagued with circuit thrombus formation while on cardiopulmonary bypass and subsequent massive hemorrhage after bypass. We review the child's anticoagulation management, clinical challenges encountered, and review current literature related to the use of argatroban in pediatric cardiac surgery.
